rs138004478
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBS1_Supporting
The NM_020800.3(IFT80):āc.721G>Cā(p.Gly241Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000731 in 1,614,156 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.00040 ( 0 hom., cov: 32)
Exomes š: 0.000039 ( 0 hom. )
Consequence
IFT80
NM_020800.3 missense
NM_020800.3 missense
Scores
11
6
2
Clinical Significance
Conservation
PhyloP100: 7.57
Genes affected
IFT80 (HGNC:29262): (intraflagellar transport 80) The protein encoded by this gene is part of the intraflagellar transport complex B and is necessary for the function of motile and sensory cilia. Defects in this gene are a cause of asphyxiating thoracic dystrophy 2 (ATD2). Three transcript variants encoding two different isoforms have been found for this gene.[provided by RefSeq, Jun 2010]
ENSG00000248710 (HGNC:56756): (TRIM59-IFT80 readthrough (NMD candidate)) This locus represents naturally occurring readthrough transcription between the neighboring TRIM59 (tripartite motif containing 59) and IFT80 (intraflagellar transport 80) genes on chromosome 3. The readthrough transcript is unlikely to produce a protein product. [provided by RefSeq, Jun 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 3-160356069-C-G is Pathogenic according to our data. Variant chr3-160356069-C-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 406218.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-160356069-C-G is described in Lovd as [Likely_pathogenic].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.0004 (61/152336) while in subpopulation AFR AF= 0.00142 (59/41570). AF 95% confidence interval is 0.00113. There are 0 homozygotes in gnomad4. There are 22 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IFT80 | ENST00000326448.12 | c.721G>C | p.Gly241Arg | missense_variant | 8/20 | 1 | NM_020800.3 | ENSP00000312778.7 | ||
ENSG00000248710 | ENST00000483754.1 | n.1234G>C | non_coding_transcript_exon_variant | 6/19 | 2 | ENSP00000456272.1 |
Frequencies
GnomAD3 genomes AF: 0.000401 AC: 61AN: 152218Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
61
AN:
152218
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000676 AC: 17AN: 251404Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135866
GnomAD3 exomes
AF:
AC:
17
AN:
251404
Hom.:
AF XY:
AC XY:
8
AN XY:
135866
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1461820Hom.: 0 Cov.: 31 AF XY: 0.0000344 AC XY: 25AN XY: 727228
GnomAD4 exome
AF:
AC:
57
AN:
1461820
Hom.:
Cov.:
31
AF XY:
AC XY:
25
AN XY:
727228
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000400 AC: 61AN: 152336Hom.: 0 Cov.: 32 AF XY: 0.000295 AC XY: 22AN XY: 74492
GnomAD4 genome
AF:
AC:
61
AN:
152336
Hom.:
Cov.:
32
AF XY:
AC XY:
22
AN XY:
74492
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
7
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
11
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Jeune thoracic dystrophy Pathogenic:3
Likely pathogenic, no assertion criteria provided | research | University of Washington Center for Mendelian Genomics, University of Washington | - | - - |
Pathogenic, no assertion criteria provided | research | Dan Cohn Lab, University Of California Los Angeles | Jun 01, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 11, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 241 of the IFT80 protein (p.Gly241Arg). This variant is present in population databases (rs138004478, gnomAD 0.1%). This missense change has been observed in individuals with short-rib thoracic dysplasia (PMID: 19648123, 29068549, 30266093). ClinVar contains an entry for this variant (Variation ID: 406218). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt IFT80 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Short-rib thoracic dysplasia 6 with or without polydactyly Pathogenic:2
Likely pathogenic, no assertion criteria provided | research | University of Washington Center for Mendelian Genomics, University of Washington | - | - - |
Pathogenic, no assertion criteria provided | research | Dan Cohn Lab, University Of California Los Angeles | Jun 01, 2017 | - - |
Asphyxiating thoracic dystrophy 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jun 01, 2023 | The IFT80 c.721G>C; p.Gly241Arg variant (rs138004478) is reported in the literature in the homozygous or compound heterozygous state in individuals affected with short-rib thoracic dysplasia II, asphyxiating thoracic dystrophy, or Jeune-Verma-Naumoff dysplasia (Cavalcanti 2011, Normand 2018, Zhang 2018). This variant is also reported in ClinVar (Variation ID: 406218), and is found in the African/African-American population with an allele frequency of 0.12% (30/24974 alleles) in the Genome Aggregation Database. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.628). Based on available information, this variant is considered to be likely pathogenic. References: Cavalcanti D et al. Mutation in IFT80 in a fetus with the phenotype of Verma-Naumoff provides molecular evidence for Jeune-Verma-Naumoff dysplasia spectrum. J Med Genet. 2011; 48(2):88-92. PMID: 19648123. Normand EA et al. Clinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder. Genome Med. 2018 Sep 28;10(1):74. PMID: 30266093. Zhang W et al. Expanding the genetic architecture and phenotypic spectrum in the skeletal ciliopathies. Hum Mutat. 2018 Jan;39(1):152-166. PMID: 29068549. - |
IFT80-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 08, 2024 | The IFT80 c.721G>C variant is predicted to result in the amino acid substitution p.Gly241Arg. This variant was reported in the homozygous state in multiple individuals with short-rib thoracic dysplasia (Cavalcanti et al. 2011. PubMed ID: 19648123; Zhang et al. 2017. PubMed ID: 29068549; Normand et al. 2018. PubMed ID: 30266093). This variant is reported in 0.12% of alleles in individuals of African descent in gnomAD. This variant is interpreted as pathogenic. - |
not provided Uncertain:1
Uncertain significance, flagged submission | clinical testing | Eurofins Ntd Llc (ga) | Mar 02, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
D;.;.;T
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;.;D;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D;D
MetaSVM
Uncertain
T
MutationAssessor
Pathogenic
H;.;.;.
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;D;D;D
REVEL
Uncertain
Sift
Pathogenic
D;D;D;D
Sift4G
Uncertain
D;D;D;D
Polyphen
D;.;.;.
Vest4
MutPred
Gain of sheet (P = 0.1208);.;.;.;
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at